About NanoViricides, Inc
- Industry: Biotechnology
- Exchange: NYSE MKT LLC
- Country: US
- Website: https://www.nanoviricides.com/
Frequently Asked Questions
What is the 52-week range for NNVC?
The 52-week high is $2.2299 and the 52-week low is $0.85.
What is the P/E ratio for NNVC?
The P/E ratio data is currently unavailable.
What is the dividend yield for NNVC?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -91.11%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.65.
Analyst Recommendation Trends
Wall Street analyst consensus for NNVC over the last few months:
Latest NNVC News
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
SHELTON, CT / ACCESS Newswire / September 29, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with the Securities and Exchange Commission (SEC) on Monday, September 28, 2026.
Nanoviricides Q4 EPS $(0.10), Inline
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 23.08 percent increase over losses of $(0.13) per share from the same period last year.
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
SHELTON, CT / ACCESS Newswire / September 28, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") has started enrolling and dosing patients at an Ebola Treatment Center in the Ituri province.
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / September 23, 2026 / , Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral Drug NV-387 as a Treatment for Monkeypox Virus Infection has begun with enrollment of first patients in the Democratic Republic of Congo (DRC).
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47% to $106.19.
These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
Biotech stocks can offer high reward opportunities. Here are three North American biotech stocks that could offer both growth and value.
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
SHELTON, CT / ACCESS Newswire / September 15, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") is scheduled to start next week at an Ebola Treatment Center in the Ituri province.
NanoViricides Announces That Its Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In Democratic Republic Of Congo Is Scheduled To Begin Next Week
Clinical trial is scheduled to start at an Ebola Treatment Center in the Ituri province."NV-387 being an oral drug with broad-spectrum antiviral properties, everyone is rooting for it and hoping that it is effective
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
SHELTON, CT / ACCESS Newswire / September 8, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") was successfully registered in the Pan African Clinical Trials Registry (pactr.
NanoViricides Says Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In DR Congo Registered In Pan African Clinical Trials Registry Database
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment